Maruho Co., Ltd.
http://www.maruho.co.jp/english/index.html
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Maruho Co., Ltd.
Asia Deal Watch: US Biotech LIB Partners In Greater China With Hasten On PCSK9 Therapy
Plus deals involving Astellas/Menarini, Maruho/Fortress Biotech, Zenas/Bristol Myers Squibb, Huadong Medicine/MC2 and more.
Galderma Readies Its First Therapeutic Biologic For Two US Launches In 2024
Galderma said its IL-31 receptor alpha inhibitor nemolizumab succeeded in two Phase III atopic dermatitis trials, advancing the firm’s long-term goal of moving past topical dermatology drugs.
Japan Q1 Roundup: Enhertu, Padcev, Actemra and Lenvima Push Growth
The main Japanese pharma players report a generally strong fiscal Q1, helped by mainstays including Daiichi Sankyo's Enhertu, Astellas's Xtandi and Padcev and Chugai's Actemra, and in some cases by the weaker yen.
Upstream Launches With $200m To Buy, Develop Drugs For Immune-Mediated Diseases
Upstream Bio acquired Phase Ib-ready UPB-101 from Astellas, and its experienced team plans to buy additional drug candidates for the treatment of allergic and inflammatory diseases.
Company Information
- Industry
-
Pharmaceuticals
- Specialty Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice